Dr. Andrew Bellinger: Verve Therapeutics on gene editing of humans to reduce bad cholesterol

We are into the age of testing gene editing on humans when it comes to looking into heart disease issues. Earlier this month a New Zealander was the first person to be injected with gene-editing instructions to try and modify a single part of their DNA to stop it producing bad cholesterol. It has been used on monkeys in the past, which resulted in a 70 percent reduction in cholesterol levels. Dr. Andrew Bellinger is the chief scientific and medical officer of Verve Therapeutics and he joined Mike Hosking. LISTEN ABOVESee omnystudio.com/listener for privacy information.